Does the media prefer VYGR or FTH?

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 2 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.83 beat Sensei Biotherapeutics' score of 0.78 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VYGR or AURA?

In the previous week, Aura Biosciences had 4 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Aura Biosciences and 2 mentions for Voyager Therapeutics. Aura Biosciences' average media sentiment score of 1.77 beat Voyager Therapeutics' score of 0.83 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer SLN or VYGR?

In the previous week, Silence Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Silence Therapeutics and 2 mentions for Voyager Therapeutics. Silence Therapeutics' average media sentiment score of 1.52 beat Voyager Therapeutics' score of 0.83 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NGNE or VYGR?

In the previous week, Neurogene had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Neurogene and 2 mentions for Voyager Therapeutics. Neurogene's average media sentiment score of 1.76 beat Voyager Therapeutics' score of 0.83 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NVCT or VYGR?

In the previous week, Nuvectis Pharma had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Nuvectis Pharma and 2 mentions for Voyager Therapeutics. Nuvectis Pharma's average media sentiment score of 0.95 beat Voyager Therapeutics' score of 0.83 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Voyager Therapeutics (VYGR) Competitors

$3.45 -0.09 (-2.54%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$3.43 -0.02 (-0.46%)

As of 04:00 AM Eastern

Compare

VYGR vs. FTH, AURA, SLN, NGNE, and NVCT

Should you buy Voyager Therapeutics stock or one of its competitors? Voyager Therapeutics's main competitors and comparable companies include Sensei Biotherapeutics (FTH), Aura Biosciences (AURA), Silence Therapeutics (SLN), Neurogene (NGNE), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Voyager Therapeutics compare to Sensei Biotherapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 2 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.83 beat Sensei Biotherapeutics' score of 0.78 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Voyager Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Voyager Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 378.26%. Sensei Biotherapeutics has a consensus target price of $55.00, indicating a potential upside of 67.84%. Given Voyager Therapeutics' higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Sensei Biotherapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Sensei Biotherapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.27	-$119.72M	-$1.80	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

Voyager Therapeutics beats Sensei Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Aura Biosciences?

Voyager Therapeutics (NASDAQ:VYGR) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Aura Biosciences had 4 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Aura Biosciences and 2 mentions for Voyager Therapeutics. Aura Biosciences' average media sentiment score of 1.77 beat Voyager Therapeutics' score of 0.83 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aura Biosciences has lower revenue, but higher earnings than Voyager Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.27	-$119.72M	-$1.80	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Voyager Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Voyager Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 378.26%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 143.73%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aura Biosciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Aura Biosciences	N/A	-73.18%	-62.00%

Summary

Voyager Therapeutics beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Silence Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Voyager Therapeutics has a net margin of -312.63% compared to Silence Therapeutics' net margin of -8,943.86%. Voyager Therapeutics' return on equity of -57.92% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

In the previous week, Silence Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Silence Therapeutics and 2 mentions for Voyager Therapeutics. Silence Therapeutics' average media sentiment score of 1.52 beat Voyager Therapeutics' score of 0.83 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Silence Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,457.94	-$88.61M	-$1.28	N/A
Voyager Therapeutics	$40.37M	5.27	-$119.72M	-$1.80	N/A

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics currently has a consensus price target of $53.50, suggesting a potential upside of 294.54%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 378.26%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Silence Therapeutics beats Voyager Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Neurogene presently has a consensus price target of $83.67, indicating a potential upside of 130.87%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 378.26%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Neurogene had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Neurogene and 2 mentions for Voyager Therapeutics. Neurogene's average media sentiment score of 1.76 beat Voyager Therapeutics' score of 0.83 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has higher earnings, but lower revenue than Voyager Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	779.74	-$90.35M	-$5.03	N/A
Voyager Therapeutics	$40.37M	5.27	-$119.72M	-$1.80	N/A

Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Neurogene has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Neurogene's return on equity of -45.10% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

52.4% of Neurogene shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Neurogene beats Voyager Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvectis Pharma presently has a consensus target price of $35.00, indicating a potential upside of 53.98%. Voyager Therapeutics has a consensus target price of $16.50, indicating a potential upside of 378.26%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Nuvectis Pharma has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

In the previous week, Nuvectis Pharma had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Nuvectis Pharma and 2 mentions for Voyager Therapeutics. Nuvectis Pharma's average media sentiment score of 0.95 beat Voyager Therapeutics' score of 0.83 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has higher earnings, but lower revenue than Voyager Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Voyager Therapeutics	$40.37M	5.27	-$119.72M	-$1.80	N/A

Summary

Nuvectis Pharma and Voyager Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$218.13M	$3.94B	$7.20B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-1.92	11.63	272.62	25.50
Price / Sales	5.27	1,348.37	625.30	97.13
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.98	16.64	10.99	6.34
Net Income	-$119.72M	-$22.72M	$3.47B	$349.45M
7 Day Performance	-0.86%	1.01%	0.10%	-0.67%
1 Month Performance	13.86%	13.06%	8.13%	4.48%
1 Year Performance	2.68%	54.94%	24.11%	14.94%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	2.7449 of 5 stars	$3.45 -2.5%	$16.50 +378.3%	+2.7%	$218.13M	$40.37M	N/A	100
FTH Sensei Biotherapeutics	4.2185 of 5 stars	$34.71 +8.5%	$55.00 +58.5%	N/A	$826.88M	N/A	N/A	40	News Coverage
AURA Aura Biosciences	2.7965 of 5 stars	$7.90 +1.3%	$17.50 +121.5%	+14.7%	$808.90M	N/A	N/A	50	Positive News
SLN Silence Therapeutics	3.0538 of 5 stars	$13.29 +0.2%	$53.50 +302.6%	+181.9%	$798.98M	$560K	N/A	100	Positive News
NGNE Neurogene	2.6626 of 5 stars	$39.64 +2.6%	$83.67 +111.1%	+96.1%	$773.03M	N/A	N/A	90	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. FTH, AURA, SLN, NGNE, and NVCT

How does Voyager Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Voyager Therapeutics compare to Aura Biosciences?

Summary

How does Voyager Therapeutics compare to Silence Therapeutics?

Summary

How does Voyager Therapeutics compare to Neurogene?

Summary

How does Voyager Therapeutics compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. FTH, AURA, SLN, NGNE, and NVCT

How does Voyager Therapeutics compare to Sensei Biotherapeutics?

Does the media prefer VYGR or FTH?

Do insiders and institutionals hold more shares of VYGR or FTH?

Which has more volatility and risk, VYGR or FTH?

Do analysts recommend VYGR or FTH?

Is VYGR or FTH more profitable?

Which has higher valuation and earnings, VYGR or FTH?

Summary

How does Voyager Therapeutics compare to Aura Biosciences?

Does the media refer more to VYGR or AURA?

Do insiders & institutionals hold more shares of VYGR or AURA?

Which has higher earnings and valuation, VYGR or AURA?

Which has more risk and volatility, VYGR or AURA?

Do analysts prefer VYGR or AURA?

Is VYGR or AURA more profitable?

Summary

How does Voyager Therapeutics compare to Silence Therapeutics?

Which has more risk and volatility, SLN or VYGR?

Is SLN or VYGR more profitable?

Does the media prefer SLN or VYGR?

Which has better earnings & valuation, SLN or VYGR?

Do insiders and institutionals have more ownership in SLN or VYGR?

Do analysts recommend SLN or VYGR?

Summary

How does Voyager Therapeutics compare to Neurogene?

Do analysts rate NGNE or VYGR?

Does the media favor NGNE or VYGR?

Which has preferable earnings and valuation, NGNE or VYGR?

Which has more risk and volatility, NGNE or VYGR?

Is NGNE or VYGR more profitable?

Do insiders & institutionals believe in NGNE or VYGR?

Summary

How does Voyager Therapeutics compare to Nuvectis Pharma?

Do insiders and institutionals hold more shares of NVCT or VYGR?

Do analysts rate NVCT or VYGR?

Is NVCT or VYGR more profitable?

Which has more risk & volatility, NVCT or VYGR?

Does the media prefer NVCT or VYGR?

Which has higher earnings and valuation, NVCT or VYGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools